SGPL1 Deficiency: A Rare Cause of Primary Adrenal Insufficiency

N Settas, R Persky, FR Faucz… - The Journal of …, 2019 - academic.oup.com
N Settas, R Persky, FR Faucz, N Sheanon, A Voutetakis, M Lodish, LA Metherell
The Journal of Clinical Endocrinology & Metabolism, 2019academic.oup.com
Context Multiple autosomal recessive genes have been etiologically linked to primary
adrenal insufficiency (PAI). Recently, sphingosine-1-phosphate lyase 1 (SGPL1) gene
mutations were recognized as a cause of steroid-resistant nephrotic syndrome type 14
(NPHS14), a sphingolipidosis with multisystemic manifestations, including PAI. Objective To
check if SGPL1 mutations are involved in the pathogenesis of PAI in patients who do not
exhibit nephrotic syndrome. Methods Sequencing of the SGPL1 gene in 21 patients with …
Context
Multiple autosomal recessive genes have been etiologically linked to primary adrenal insufficiency (PAI). Recently, sphingosine-1-phosphate lyase 1 (SGPL1) gene mutations were recognized as a cause of steroid-resistant nephrotic syndrome type 14 (NPHS14), a sphingolipidosis with multisystemic manifestations, including PAI.
Objective
To check if SGPL1 mutations are involved in the pathogenesis of PAI in patients who do not exhibit nephrotic syndrome.
Methods
Sequencing of the SGPL1 gene in 21 patients with familial glucocorticoid disease or triple A syndrome.
Results
We identified two missense SGPL1 variants in four patients, two of whom were first cousins. We describe in detail the proband, a boy born to Saudi Arabian consanguineous parents with a homozygous c.665G>A, p.R222Q SGPL1 variant. The patient presented with hypoglycemia and seizures at age 2 years and was ultimately diagnosed with PAI (isolated glucocorticoid deficiency). Brain MRI showed abnormalities in the basal ganglia consistent with a degenerative process albeit the patient had no neurologic symptoms.
Conclusions
New genetic causes of PAI continue to be identified. We suggest that screening for SGPL1 mutations should not be reserved only for patients with nephrotic syndrome but may also include patients with PAI who lack other clinical manifestations of NPHS14 because, in certain cases, kidney disease and accompanying features might develop. Timely diagnosis of this specific sphingolipidosis while the kidneys still function normally can lead to prompt initiation of therapy and improve outcome.
Oxford University Press